# US 2008/0286774 A1 · Real-time individualized therapy evaluation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0286774 A1
- Document ID: US20080286774A1
- Status: Published application
- Kind: A1
- Application number: 11/821,174
- Filed: 2007-06-21
- Published: 2008-11-20
- Earliest claimed: 2007-05-16
- Assignees: The Regents of the University of California
- Inventors: Kenneth W. Turteltaub; Paul T. Henderson; Sang Soo Hah
- Web page: https://patentgrep.com/patent/US20080286774A1

## CPC

- G01N 33/582: {with fluorescent label}
- G01N 33/5088: {of vertebrates}
- G01N 33/60: involving radioactive labelled substances
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A method of individually optimizing drug therapy to a patient that includes the steps of administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy, collecting a sample from the patient, analyzing the sample producing an analysis, and using the analysis for developing a model for the patient.

## Claims

### Claim 1

A method of individually optimizing drug therapy to a patient, comprising the steps of:
administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy,
collecting a sample from the patient,
analyzing said sample producing an analysis, and
using said analysis for developing a model for the patient.

### Claim 2 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by accelerator mass spectrometry producing an accelerator mass spectrometry analysis.

### Claim 3 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by analyzing said sample with sensitive fluorimeters producing a fluorimeters analysis.

### Claim 4 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by accelerator mass spectrometry producing an accelerator mass spectrometry analysis, and wherein said step of using said analysis for developing a model for the patient comprises using said accelerator mass spectrometry analysis for developing a model for the patient.

### Claim 5 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a pharmacokinetic model for the patient.

### Claim 6 (depends on 5)

The method of individually optimizing drug therapy to a patient of claim 5 including using said pharmacokinetic model to select an optimal drug dose, type and dosing interval for the patient.

### Claim 7 (depends on 5)

The method of individually optimizing drug therapy to a patient of claim 5 including collecting an additional sample from the patient to continuously monitor the status of the therapy and detect any changes in the metabolic and kinetic profile to signify development of resistance to the drug.

### Claim 8 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a metabolites model for the patient.

### Claim 9 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a DNA adducts model for the patient.

### Claim 10 (depends on 9)

The method of individually optimizing drug therapy to a patient of claim 9 wherein said step of developing a DNA adducts model for the patient provides information regarding DNA-drug adduct formed for drugs designed to bind to DNA.

### Claim 11 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of collecting a sample from the patient comprises collecting a blood sample.

### Claim 12 (depends on 1)

The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of collecting a sample from the patient comprises collecting a tissue sample.

### Claim 13

A method of individually optimizing drug therapy to a patient, comprising the steps of:
administering a dose of a radiolabeled drug to the patient in connection with chemotherapy,
collecting a sample from the patient,
analyzing said sample by accelerator mass spectrometry producing an analysis, and
using said analysis for developing a model for the patient.

### Claim 14 (depends on 13)

The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a pharmacokinetic model for the patient.

### Claim 15 (depends on 4)

The method of individually optimizing drug therapy to a patient of claim 4 including using said pharmacokinetic model to select an optimal drug dose, type and dosing interval for the patient.

### Claim 16 (depends on 4)

The method of individually optimizing drug therapy to a patient of claim 4 including collecting an additional sample from the patient to continuously monitor the status of the therapy and detect any changes in the metabolic and kinetic profile to signify development of resistance to the drug.

### Claim 17 (depends on 13)

The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a metabolites model for the patient.

### Claim 18 (depends on 13)

The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a DNA adducts model for the patient.

### Claim 19 (depends on 8)

The method of individually optimizing drug therapy to a patient of claim 8 wherein said step of developing a DNA adducts model for the patient provides information regarding DNA-drug adduct formed for drugs designed to bind to DNA.

### Claim 20 (depends on 13)

The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of collecting a sample from the patient comprises collecting a blood sample.

### Claim 21 (depends on 13)

The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of collecting a sample from the patient comprises collecting a tissue sample.
